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Admirable as it is, the drug discovery and development process is continuously undergoing changes and
adjustments in search of further improvements in efficiency, productivity, and profitability. Recent trends
in academic-industrial partnerships promise to provide new opportunities for advancements of this process
through transdisciplinary collaborations along the entire spectrum of activities involved in this complex pro-
cess. This perspective discusses ways to promote the emerging academic paradigm of the chemistry-
biology-medicine continuum as a means to advance the drug discovery and development process.Emerging in the early decades of the 19th century, modern chem-
istry, organic synthesis in particular, played a major role in the
evolution of science by providingmolecules, natural or designed,
for further investigations and applications. Various enterprises,
most notably the dye and pharmaceutical industries, relied
heavily for their establishment and advancement on discoveries
and inventions in organic synthesis. During the nineteenth and
early twentieth centuries, this discipline remained for the most
part an isolated science in academia, whose practitioners were
interested primarily in advancing it for its own sake through
discovery and development of new synthetic reactions and their
applications to natural products chemistry. The latter were
considered as targets for structural elucidation and total synthe-
sis. This paradigm changed significantly in the second half of the
twentieth century when a number of investigators turned their
attention to producing sufficient quantities of scarce natural
products for biological studies and medical applications.
Following the discovery and development of penicillin as an anti-
biotic, the pharmaceutical industry intensified its activities in the
isolation and development of natural products as drugs while at
the same time it began to exploit the increasing power of organic
synthesis to design, synthesize, and test small organic mole-
cules as potential drug candidates through what became known
as medicinal chemistry. The process of rational drug design
based on the identification and validation of a biological target
followed by medicinal chemistry to find small molecules that
would bind and modulate the function of the biological target
became the standard paradigm for the drug discovery and
development process during the last decades of the twentieth
century. At the same time, chemists and biologists in academia
began to recognize and appreciate the importance and potential
impact of merging their efforts toward the elucidation of biolog-
ical pathways and disease pathogenesis.
This drive toward merging chemistry and biology gave birth to
chemical biology (Schreiber and Nicolaou, 1994a, 1994b), an
umbrella scientific discipline; one of the main areas of investiga-
tion of this domain is the synthesis and use of small organic mol-
ecules of natural or designed origins to probe human biology as a
means to gain new fundamental knowledge and pave theway forChemistry & Biology 2drug discovery and development (Nicolaou, 2013, 2014b; Nico-
laou andMontagnon, 2008; Schreiber, 2011;Wetzel et al., 2011).
Tools to elucidate biological pathways and lead compounds for
drug discovery are two of the most important objectives of
organic synthesis and chemical biology today. The merging of
chemistry and biology in academia is now expanding to include
drug discovery and development (Waldmann, 2012), often in
collaboration with industry. Indeed, during the last 25 years
or so a number of lead compounds and drug candidates
were developed into approved clinical drugs through partner-
ships with pharmaceutical and biotechnology companies.
Notable examples of such successes include pemetrexed
(Alimta, approved 2004) (Taylor, 2011), emtricitabine (Emtriva,
approved 2003) (Furman et al., 1992; Saag, 2006), vorinostat
(Zolinza, approved 2006) (Marks and Breslow, 2007), pregabalin
(Lyrica, approved 2004) (Silverman, 2008), and eribulin (Halaven,
approved 2010) (Towle et al., 2001; Yu et al., 2005) (Figure 1).
Currently, collaborative research programs between academic
and industrial partners are on the increase, leading to the new
paradigm of drug discovery and development through aca-
demic-industrial (or private-public) partnerships (Nicolaou,
2014a). An example of this is the Accelerating Medicines Part-
nership between the National Institutes of Health (USA) and ten
biopharmaceutical companies and various nonprofit organiza-
tions to tackle Alzheimer’s, type II diabetes, lupus, and rheuma-
toid arthritis.
The chemistry-biology-medicine paradigm in academia paral-
lels the traditional drug discovery and development process
practiced in the pharmaceutical and biotechnology sectors
but differs in some respects and should differ from it in a num-
ber of important ways. The chemistry-biology-medicine contin-
uum of research in academia may cover the entire spectrum of
activities of the drug discovery and development process
(Figure 2) (Nicolaou, 2014b) from pathogenesis of the disease
and target identification and validation to lead discovery and
optimization and clinical trials, although the latter most likely
will need industrial partnerships for technical and financial sup-
port. Given the mission of academia, these research and devel-
opment activities ought to be focused on different or modified1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1039
Figure 1. Examples of Drugs Discovered and Developed through
Academic-Industrial Partnerships
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advance the core sciences involved, (2) potential to lead to new
principles and paradigms for the drug discovery and develop-
ment process, and (3) potential to maximize and balance the
high risk/high impact relationship. Due to their complexity
and resource demanding nature, these partnerships are almost
always obligatory and could include transdisciplinary aca-
demic-academic and academic-industrial partnerships among
chemists, biologists, computational scientists, and clinicians,
and more broadly patients, patient group advocates, policy
makers, regulators, and the general public. These initiatives
should be undertaken with great wisdom in order to create op-
portunities that encourage and maintain academic freedom
to discover and disseminate scientific knowledge, result in
educationally and scientifically challenging and meaningful pro-
grams and benefit and reward all participants and stakeholders
(Nicolaou, 2014a).
Making Transdisciplinary Research at the Chemistry-
Biology-Medicine Continuum a Reality
Although interdisciplinary research at the interface of chemistry
and biology in academia has been a tradition for some time,
such programs are still on the rise. They are becoming more
crucial for success due to the increasing complexity of biomed-
ical research and the new trends and emerging paradigms within
the drug discovery and development process, such as:
Increasing academic-industrial partnerships
Renaissance in natural product chemistry, biology, and
medicine
Antibody-drug conjugates
Involvement of clinicians in the early stages of drug discovery
and development
Patient-derived xenografts (PDXs)
Cancer stem cell biology and targeting for chemotherapy
purposes
Phenotypic screening1040 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier LtSynthetic method development, novel structural motifs, and
drug design synergies
Rare diseases
Biomarkers
Introducing fluorine 19F and 18F into drug candidates and
imaging agents, respectively
Computational and cognitive sciences
These endeavors are becoming more multidisciplinary and
transdisciplinary, meaning that more disciplines and closer inter-
actions and exchanges among the participants are required to
solve newly defined challenges and exploit the opportunities
they present. Such transdisciplinary research may include not
only chemistry and biology but also new disciplines, such as
bioengineering, nanotechnology, and computational sciences
whose potential to contribute to and benefit from such en-
deavors are becoming evident. Prominent among them are
computational science and drug discovery and development,
the latter being the ultimate goal of biomedical research (Nico-
laou, 2014b).
The reliance of the pharmaceutical enterprise on fundamental
discoveries in chemistry and biology provides enormous divi-
dends to society. While the majority of these basic discoveries
were made in academia, a good number of them resulted from
research in pharmaceutical and biotechnology companies.
Pressures in industry in recent years, however, led to shifting
priorities and decreasing support for internal basic research,
compelling pharmaceutical and biotechnology companies
to rely more on academic discoveries to provide the founda-
tions for their research directions and drug discovery efforts.
This paradigm necessitates strategic collaborations between
academia and industry, which are currently on the rise and
in flux. There are a number of strengths and benefits of aca-
demic-industrial partnerships, for example:
Complementarity of academic and industrial expertise
New funding opportunities for academics
Potential financial benefits for academic investigators and
institutions
Acceleration of translational research
Enhancement of multi- and transdisciplinary research
Enrichment of education and training
Bridging the gap between discovery and clinical develop-
ment
However, there are also challenging issues of academic-
industrial partnerships as illustrated by the following points:
Timely dissemination of results in lectures and publications
Less fundamental and curiosity-driven research
Issues with career development and job hunting for students
due to confidentiality restrictions
Differences in culture, mission, and operation
Potential negative impact on academic freedom
Licensing and royalties
Time pressures and deliverables
Thus, for such partnerships to be successful, a number of
criteria have to be fulfilled and their specific aims carefully
defined. The first issue is how to bring the two cultures togetherd All rights reserved
Figure 2. The Modern Drug Discovery and Development Process
The current paradigm of the process (main pipeline, center) begins with the pathogenesis of the disease and identification and validation of the biological target(s)
associated with it as well as the identification of biomarkers which become indispensable in personalized medicine (first box, center, from left to right). Screening
of compound libraries against the target(s) to identify lead compounds (second box, center) is followed by optimization and selection of preclinical candidates
(third box, center) and subsequent preclinical studies that lead to the identification of clinical candidates (fourth box, center). Alternatively, phenotypic screening
of compound libraries in biological and pharmacological assays in cells, tissues, or whole organisms (third and fourth boxes, bottom) may precede target
identification. Clinical trials phase I, II, and III (fifth box, center) then follow, and, if successful, a new drug application (NDA) is submitted (sixth box, center) to the
appropriate agencies for approval as a clinical agent (seventh box, center). The boxes above and below the main drug pipeline (center) summarize the primary
driver disciplines and useful technologies and assets deployed in the advancement of the process along the pathway from the identification and pathogenesis of
the disease to approval. The current average rate of success of small molecule drug candidates is in the single digits (modified from Nicolaou, 2014b).
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of thought and enjoy the privilege of curiosity-driven research,
as opposed to scientists in industry who are constrained by time-
lines and other pressures that limit their pursuits to highly
focused, streamlined, and mission-oriented discovery pro-
grams. The latter are also restricted by intellectual property con-
siderations that compromise the timely dissemination of their
findings while the former are under pressure to disclose their dis-
coveries on basic research to the scientific community at large
as quickly as possible. On the other hand, scientists in industry
often have access to more resources and support facilities and
staff to their disposal as compared to academic investigators.
The issue of intellectual property (IP) and royalties are often
thorny and require patience for resolution. Facing these chal-
lenges and balancing the benefits versus the disadvantages is
not always an easy task. Bridging the differences, however, is
a priority and should be based on mutual respect of the cultures
and interests of each side and, above all, trust. The gap may
seem wide, but once the specific goals and missions for each
side are clearly defined, the parties can settle on a structure
that provides the necessary incentives and enthusiasm for suc-
cess as appropriate in each case (Nicolaou, 2014a).
The emerging chemistry-biology-medicine research paradigm
in academia may manifest itself in a variety of ways in an
increasing number of areas. Thus, for example, chemistry-driven
research programs may be initiated by academic investigators
in collaborations with biologists and clinicians that involve chem-
ical synthesis of natural or designedmolecules for evaluations as
potential biological tools, lead compounds or drug candidates.
Strongly supported along the drug discovery and developmentChemistry & Biology 2pathway by experts from each domain at each stage, such part-
nerships could become powerful vehicles for advancing the sci-
ences of chemistry and biology, improving the drug discovery
and development process, facilitating diagnosis of disease,
and delivering new drugs. Another emerging paradigm that
may involve chemists and clinicians is the design, synthesis
and evaluation/utilization of imaging agents such as compounds
containing 18F, the latter being suitable for positron emission
topography (PET), a highly desirable imaging clinical technique
(Kamlet et al., 2013; Tredwell andGouverneur, 2012). The advan-
tages of PET, however, are compromised by the half-life of 18F
that requires short reaction times and rapid transfer to the pa-
tient, necessitating special innovations in chemistry and direct
interactions of the chemists with clinicians who have access to
the patients. The continuously emerging new synthetic technol-
ogies for introducing fluorine residues in organic molecules for
drug discovery purposes in general, are providing crucial sup-
port to these programs.
Other paradigms of particular relevance to the chemistry-
biology-medicine continuum include orphan or rare diseases
(Jarvis, 2013; Klein, 2009) and cancer (Williams et al., 2013).
Attending the bedside of the patient, clinicians can play major
roles in the diagnosis and etiology of rare diseases (Jarvis,
2013; Klein, 2009) and deciphering the pathogenesis of newly
identified ones. Further biological studies may then be under-
taken to fully understand the human biology involved in these
diseases with the goal of identifying and validating the relevant
biological target(s), at which point chemists can step in to
discover enabling biological tools and drug candidates for devel-
opment as therapeutic agents to complement any cell, enzyme1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1041
Chemistry & Biology
Perspectiveor gene therapies that may have been developed in the mean-
time. These academic-medical collaborations may benefit by
partnerships with pharmaceutical and biotechnology companies
that can bridge the gap between academia and the clinic in terms
of preclinical studies of discovered drug candidates. These drug
candidates can then be tested for their efficacy and safety by
these same physicians who may have initiated the programs in
the first place.
The advents of cancer stem cells (CSCs) and patient-derived
xenografts (PDXs) (Williams et al., 2013) provide further opportu-
nities to expand the chemistry-biology axis to include the clinic
into the biomedical research continuum and extend the tradi-
tional role of clinicians in carrying out the clinical phase of drug
development by engaging them in the earlier stages of the
drug discovery process. Recent discoveries in cancer biology
place cancer stem cells on center stage as drivers for cancer
growth, proliferation, drug resistance and recurrence. It is, there-
fore, of paramount importance not only to categorize cancer pa-
tients at the personal level but also to define their cancer stem
cells at the molecular level through biomarker identification in
order to provide guidance for the development of personalized
and effective medicines to treat and cure their cancers. PDXs
have recently emerged as superior models for evaluating the ef-
ficacy of cancer drug candidates because of their closer simula-
tion of human clinical conditions. Pathologists, oncologists, and
surgeons are positioned to assist in bringing such cells and
tissue specimens into the drug discovery and development
process by virtue of their expertise and proximity to patients,
thus making the academic chemistry-biology-medicine alliance
a forceful new paradigm in biomedical research. To be sure,
patients and their advocates will provide their support for this
involvement. The various institutions involved should also
move decisively toward resolving the remaining challenges and
issues as they position themselves to support these collabora-
tions and partnerships (Williams et al., 2013).
Biological Target Identification and Validation
The process of target identification and validation is of extreme
importance to the drug discovery and development process
(Benjamin et al., 2012; Cong et al., 2012; Futamura et al., 2013;
Moellering and Cravatt, 2012; Prinz et al., 2011; Schenone
et al., 2013). It often defines not only the start of the process
but also the end, given that clinical success of a drug candidate
hinges heavily on the full understanding and relevance of the
biological target to the intended disease. Indeed, ill-defined
and partially validated targets have been increasingly associated
with the high attrition rates of drug candidates as their modula-
tion does not lead to the expected efficacy in treating the disease
or may result in side effects. The previously adopted and
currently widely used paradigm of identifying a biological target
against which compound libraries are screened in order to
discover lead compounds for optimization serves well in the
early stages of the drug discovery and development process
but often fails to predict pharmacological properties and clinical
efficacy. It has recently been argued that phenotypic and phar-
macological testing in cells, tissues and whole organisms of
compound librariesmay have certain advantages over screening
against the biological target in that it increases predictivity of
pharmacological success in the latter stages of the process1042 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Lt(Cong et al., 2012; Futamura et al., 2013; Moellering and Cravatt,
2012; Schenone et al., 2013; Swinney and Anthony, 2011). This
so-called chemical genomics paradigm, however, requires iden-
tification of the biological target once active compounds are
discovered. Irrespective of which paradigm is employed, the
two approaches should merge as soon as possible so as to pro-
ceed to the validation stage with parallel and simultaneous ef-
forts involving molecular target screening and pharmacological
testing in order to avoid surprises at the later stages of develop-
ment. Target identification remains a challenging task requiring
new tools, methods, and strategies. Thus, the traditional direct
biochemical methods involving affinity chromatography are
continuously augmented and improved by the development of
new techniques. Genetic and genomic methods using knockout
animal species, RNAi profiling, and small molecules with well-
defined mechanisms of action are routinely employed to identify
biological targets, especially after phenotype observations.
Combined with bioinformatics and computational inference
methods, these approaches are poised to sharpen our ability
to identify and validate biological targets. Chemical genomics,
employing phenotype screening followed by target identification
and validation requires continuous build-up of high quality com-
pound libraries enriched with novel molecular structures and
new reagents and methods for chemical proteomics and imag-
ing studies, all presenting challenges and opportunities for syn-
thetic organic chemists. The Chemical Genomics Center at the
National Institutes of Health (USA) provides an example of how
these technologies are enabling chemical biology studies and,
potentially, drug discovery efforts.
Disease-associated biomarkers are of great importance to
drug discovery, clinical development, and prescription, espe-
cially aswemove into the era of personalizedmedicine (Armitage
and Barbas, 2014; Henry and Hayes, 2012; Williams et al., 2013).
For example, and asmentioned above, cancer stem cells (CSCs)
and their biomarkers are increasingly recognized as a new para-
digm for targeted chemotherapy due to their link to the genesis,
evolution, and heterogeneity of cancer (Williams et al., 2013).
Investigations directed toward elucidating such complex biolog-
ical systems can be greatly facilitated further by increased
collaborations and alliances among academic and industrial
groups. Such partnerships are indeed essential for accelerating
the drug discovery and development process and lowering its
attrition rates. In this context, chemistry can facilitate endeavors
in target and biomarker identification through the development
of new and improved analytical and synthetic techniques.
Exploration of Nature’s Molecular Diversity
Exploring nature’s molecular diversity and understanding its
biology continues to be enormously valuable for advancements
in chemistry, physiology, and medicine (Newman and Cragg,
2012; Nicolaou et al., 2012). Whereas nucleic acids and proteins
can serve as biological targets, secondary metabolites (i.e., nat-
ural products) are valuable ligands as biological probes, lead
compounds, and drug candidates. In addition, natural products
provide inspiration and challenges for organic synthesis, chem-
ical biology, and biosynthesis research efforts. The discoveries
of aspirin, penicillin, and taxol are exemplary in that respect,
for they not only provided lasting medications for people but
also advanced the sciences of chemistry, biology, and medicined All rights reserved
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biological pathways, and novel treatments of disease (Nicolaou
and Montagnon, 2008). The fact that the majority of biodiversity
around the world remains unexplored coupled with the impres-
sive record of success of natural products provides a compelling
case for continued explorations of the forests, soil, and oceans
for further clues to be discovered, translated, and developed
into new science and medicines. Unfortunately, the pharmaceu-
tical industry has disinvested considerably from the natural prod-
ucts field in recent years primarily due to the required long term
commitment to such projects and the organic synthesis-driven
ease of access to small molecules as lead compounds and
drug candidates. The present trend toward transdisciplinary
partnerships between academia and industry provides new
opportunities and dictates renewed initiatives supported by
both industrial and government institutions. Augmented by
new analytical techniques, modern instrumentation and high
tech exploration vehicles and equipment, such explorations of
the unknown parts of the Earth may reveal untold treasures for
chemistry, biology and medicine. Biosynthetic techniques
relying on genetic engineering and synthetic biology offer an
alternative and complementary approach to the production of
natural products and their analogs. These objectives required,
however, long term vision, appreciation of the importance and
value of fundamental research, and new resources.
Synthesis and Biological Evaluation of Natural Products
and Other Molecules Like Them
Scarce bioactive naturally occurring substances are of special
interest because they are likely to remain unexplored unless
they become readily available through laboratory techniques.
Such compounds are ideal targets for total chemical synthesis
(Nicolaou et al., 2012), or synthetic biology (Carothers et al.,
2009; Weeks and Chang, 2011) (once their biosynthesis is eluci-
dated). Either or both practices may render them readily avail-
able in sufficient quantities for further biological investigations,
which may, in turn, justify further studies to determine their phar-
macological profiles that may lead to their clinical development
and medical applications. Most importantly, employing the
developed synthetic technologies, designed and otherwise inac-
cessible analogs of these molecules may be synthesized and
tested for optimization purposes. The numerous examples of
successful efforts in this arena over the years should serve as
the motivation for intensifying such research programs, whose
successes hinge decisively on fueling both the discovery of
new natural products and their total synthesis (Newman and
Cragg, 2012; Nicolaou et al., 2012) and biosynthesis (Walsh
and Fischbach, 2010; Weeks and Chang, 2011).
The relatively recent advent of antibody drug conjugates
(ADCs) (Chari et al., 2014; Dosio et al., 2014; Gerber et al.,
2013; Perez et al., 2014; Sapra and Shor, 2013; Sievers and Sen-
ter, 2013) provides special impetus to natural products isolation,
synthesis, and structural modification. Applied primarily in tar-
geted cancer chemotherapy, ADCs require the development of
specific antibodies (Hoogenboom, 2005) onto which highly cyto-
toxic compounds (often rare naturally occurring substances or
their analogs) are attached as payloads through chemical
linkers. Projects to develop such sophisticated drugs demand
a wide spectrum of research activities and expertise along theChemistry & Biology 2chemistry-biology-medicine continuum ranging from biological
target identification and validation, biomarker identification, can-
cer stem cell isolation and understanding and antibody develop-
ment to chemical synthesis, pharmacology, and clinical trials.
Such multitask projects demand multidisciplinary structures
and serve as drivers for academic-industrial-medical collabora-
tions and partnerships. The discoveries of calicheamicin g1
I,
maytansine, and dolostatin and their synthesis and modification
allowed the development of the ADC drugs Mylotarg (Lederle
Laboratories/Wyeth/Pfizer, approved 2000, withdrawn 2010),
Kadcyla (Genentech/Roche, approved 2013), and Adcetris
(Seattle Genetics and Millenium/Takeda, approved 2011),
respectively), demonstrating this new paradigm and providing
inspiration and confidence for further investment in the field.
Indeed, numerous ADCs are currently in clinical development
and many more are in earlier stages of discovery and develop-
ment (America’s Biopharmaceutical Research Companies,
2013a, 2013b). In addition to the payloads, linker technologies
(Chari et al., 2014; Perez et al., 2014; Sievers and Senter, 2013)
for ADCs are also in demand and present their own challenges
and opportunities. One of the most successful linkers to be
developed thus far is the enzymatically cleavable (by cathepsin)
valine-citrulline peptide moiety, which proved its value in the
success of Adcetris. The discovery and development of other
cleavable (chemically or enzymatically) linkers possessing the
required balance of robustness prior to entrance into the tar-
geted cells and cleavability within these cells would be another
important area of interface in chemistry, biology, and medicine.
Noncleavable linkers are also applicable provided their remnants
do not affect the bioactivity of the payload upon degradation of
the carrier antibody within the targeted cell. In addition to the
high potency required for the drug, molecular scaffolds, and syn-
thetic technologies are also needed to allow attachment of the
payload onto the antibody without compromising the cell recog-
nition ability of the latter, with the minimum number of payload
molecules per antibody molecule preferred. Similarly, biomarker
research (Armitage and Barbas, 2014; Henry and Hayes, 2012;
Williams et al., 2013) straddles the disciplines of chemistry,
biology, and medicine and is important for developing cell-
specific antibodies, recognizing the targeted cells, and identi-
fying patient populations for specific treatments. The advent of
personalized medicine and the realization of its importance is a
strong driver for such interface programs and multidisciplinary
collaborations, especially in the area of cancer chemotherapy
and cancer stem cell biology as mentioned above (Williams
et al., 2013).
Synthetic Methods, Structural Motifs, and
Molecular Diversity
Although the domain of synthetic method development has
traditionally been, for the most part, a thematic area of research,
this discipline has recently been widened to include addressing
the needs of other areas such as total synthesis, medicinal
chemistry, and chemical biology. The emergence of the
chemistry-biology-medicine continuum as a unified paradigm
cemented by the overarching domain of biomedical research
and drug discovery and development provides new challenges
and opportunities for the synthetic method development
field and its practitioners. Thus, the discovery and development1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1043
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tion of the scope and generality of the new reactions with com-
pounds relevant to biology and medicine, especially if the
method leads to new structural motifs and molecular diversity
or provides more efficient, practical, and cost effective routes
to compounds useful for biological and pharmaceutical pur-
poses (Dai et al., 2011). Collaborative efforts at these interfaces
involving academic-academic and academic-industrial partner-
ships should be encouraged and fueled by industry, start-
up companies, and Federal and State funding agencies. An
example of the latter is the Cancer Prevention and Research
Institute of Texas (CPRIT), which funds academic cancer
research and industrial commercialization of products for cancer
prevention and treatment. Such transdisciplinary research ef-
forts would increase the awareness of the needs and capabilities
of the various disciplines, thereby inspiring, driving, and focusing
research on important problems to be solved and powerful
methods to be applied in the various areas of science and tech-
nology covered by the collaborations and partnerships. Such
research programs would also promote the use of hitherto ne-
glected chemical reactions that form the huge armamentarium
of organic synthesis and have been underutilized due to various
reasons, including, to a considerable measure, lack of aware-
ness of the needs of biology and medicine in terms of sharper
tools and improved drug candidates (Nicolaou, 2014b). Lying
between organic synthesis and drug discovery, chemical biology
relies heavily on selective molecular probes for its discoveries.
Prudent designs of synthetic strategies and method develop-
ment to match molecular designs for chemical biology studies
are highly fruitful and productive in terms of delivering, in addition
to new molecular space for further biological investigations and
screening, useful chemistry, and novel lead compounds for drug
discovery and development purposes (Schreiber, 2011; Wetzel
et al., 2011).
Computational Sciences, Chemistry and Biology,
and the Drug Discovery and Development Process
Advances in computational (Sliwoski et al., 2014) and cognitive
sciences (Parmenides Foundation, 2014) combined with bio-
and cheminformatics could provide important auxiliary tools
for chemists and biologists as they attempt to navigate their
efforts in chemical biology and the drug discovery and
development process (Figure 2, top). Collaborative research at
these interfaces involving chemists, biologists, computational
scientists, and logicians, among others, could have enormous
consequences in ligand matching with biological receptors
and for drug design purposes. The dream of biologists and
drug designers of being able to design a molecule that would
bind selectively to a given biological target and possess the
proper biological and pharmacological properties can only
come true through such partnerships working in a transdisci-
plinary manner. Coupled with equally valuable developments
in automation in preparative organic chemistry driven by collab-
orative efforts among synthetic organic chemists, computer sci-
entists, and engineers, such successes in computational drug
design have the potential to revolutionize organic synthesis,
chemical biology and the drug discovery and development
process in terms of speed, reproducibility, predictivity, and
efficiency.1044 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier LtConclusion and Future Perspectives
What started in academia as a shy and reserved interface of
chemistry and biology in the last century is now in full throttle
and moving to embrace the clinic as well. What is driving this
movement is the grand challenge of advancing and accelerating
the drug discovery and development process (Figure 2) (Nico-
laou, 2014b). Indeed, the chemistry-biology-medicine contin-
uum presents a view of the broader activities and objectives
of these disciplines, defines the capabilities and limitations of
the drug discovery and development process, and offers a
vision for its future. The condition and capabilities and produc-
tivity of the biomedical enterprise and drug discovery and devel-
opment process can only be improved and advanced through
the merger and synergy of these sciences. Amalgamated
research programs within this expanded scientific landscape
should, therefore, be encouraged and nourished. Education
and training of young scientists along the same spectrum of sci-
entific disciplines should also be established and advanced
in academic institutions through appropriate curricula and
research programs to provide the essential talent and expertise.
The overarching objectives should be directed toward pushing
the frontiers of fundamental science in chemistry, biology, and
medicine, expediting translation of fundamental discoveries
into new and better drugs, especially for currently untreated
and uncurable conditions, and advancing the overall drug dis-
covery and development process to higher levels of efficiency
and productivity.
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